Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression

• Status: Recruiting
• Trial end date: 2024-11-01

Summary

This is an open-label, single arm, multicenter phase II study evaluating treatment with pembrolizumab in combination with paclitaxel in patients with locally advanced or metastatic non-luminal Hormone receptor-positive, HER2-negative (hereafter referred to as HR+/HER2-) breast cancer who had recurrence or progression while receiving previous therapy with a CDK inhibitor in the adjuvant setting or to treat advanced disease (or both).

• Phase: Phase 2

Details

• Lead Sponsor: SOLTI Breast Cancer Research Group
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Albumin-Bound Paclitaxel; Hormones; Paclitaxel; Pembrolizumab